Literature DB >> 20484086

Th17/Treg ratio in human graft-versus-host disease.

Philippe Ratajczak1, Anne Janin, Regis Peffault de Latour, Christophe Leboeuf, Allison Desveaux, Keyvan Keyvanfar, Marie Robin, Emmanuel Clave, Corine Douay, Anne Quinquenel, Claire Pichereau, Philippe Bertheau, Jean Yves Mary, Gérard Socié.   

Abstract

Th17 cells have never been explored in human graft-versus-host disease (GVHD). We studied the correlation between the presence of Th17 cells with histologic and clinical parameters. We first analyzed a cohort of 40 patients with GVHD of the gastrointestinal tract. Tumor necrosis factor (TNF), TNF receptors, and Fas expression, and apoptotic cells, CD4(+)IL-17(+) cells (Th17), and CD4(+)Foxp3(+) cells (Treg) were quantified. A Th17/Treg ratio less than 1 correlated both with the clinical diagnosis (P < .001) and more than 2 pathologic grades (P < .001). A Th17/Treg ratio less than 1 also correlated with the intensity of apoptosis of epithelial cells (P = .03), Fas expression in the cellular infiltrate (P = .003), TNF, and TNF receptor expression (P < .001). We then assessed Th17/Treg ratio in 2 other independent cohorts; a second cohort of 30 patients and confirmed that Th17/Treg ratio less than 1 correlated with the pathologic grade of GI GVHD. Finally, 15 patients with skin GVHD and 11 patients with skin rash but without pathologic GVHD were studied. Results in this third cohort of patients with skin disease confirmed those found in patients with GI GVHD. These analyses in 96 patients suggest that Th17/Treg ratio could be a sensitive and specific pathologic in situ biomarker of GVHD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484086      PMCID: PMC3001485          DOI: 10.1182/blood-2009-12-255810

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  T(H)-17 differentiation: of mice and men.

Authors:  Arian Laurence; John J O'Shea
Journal:  Nat Immunol       Date:  2007-09       Impact factor: 25.606

Review 2.  Th17 cell differentiation: the long and winding road.

Authors:  Mandy J McGeachy; Daniel J Cua
Journal:  Immunity       Date:  2008-04       Impact factor: 31.745

3.  Increased expression of interleukin 17 in inflammatory bowel disease.

Authors:  S Fujino; A Andoh; S Bamba; A Ogawa; K Hata; Y Araki; T Bamba; Y Fujiyama
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

4.  A comparison of confidence interval methods for the intraclass correlation coefficient.

Authors:  A Donner; G Wells
Journal:  Biometrics       Date:  1986-06       Impact factor: 2.571

Review 5.  T(H)-17 cells in the circle of immunity and autoimmunity.

Authors:  Estelle Bettelli; Mohamed Oukka; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2007-04       Impact factor: 25.606

6.  Donor-derived cells and human graft-versus-host disease of the skin.

Authors:  Hideyuki Murata; Anne Janin; Christophe Leboeuf; Jean Soulier; Eliane Gluckman; Veronique Meignin; Gerard Socie
Journal:  Blood       Date:  2006-11-14       Impact factor: 22.113

7.  Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression.

Authors:  Gérard Socié; Jean-Yves Mary; Marc Lemann; Marjan Daneshpouy; Philippe Guardiola; Véronique Meignin; Lionel Ades; Hélène Esperou; Patricia Ribaud; Agnés Devergie; Eliane Gluckman; Jean-Claude Ameisen; Anne Janin
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

8.  Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes.

Authors:  Jérôme Pène; Sylvie Chevalier; Laurence Preisser; Emilie Vénéreau; Marie-Hélène Guilleux; Soufiane Ghannam; Jean-Pierre Molès; Yannic Danger; Elisa Ravon; Sabine Lesaux; Hans Yssel; Hugues Gascan
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

Review 9.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

10.  Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease.

Authors:  Xiao Chen; Sanja Vodanovic-Jankovic; Bryon Johnson; Melissa Keller; Richard Komorowski; William R Drobyski
Journal:  Blood       Date:  2007-08-10       Impact factor: 22.113

View more
  51 in total

1.  Impaired regulatory T cell reconstitution in patients with acute graft-versus-host disease and cytomegalovirus infection after allogeneic bone marrow transplantation.

Authors:  Alain M Ngoma; Kazuhiko Ikeda; Yuko Hashimoto; Kazuhiro Mochizuki; Hiroshi Takahashi; Hideki Sano; Hayato Matsumoto; Hideyoshi Noji; Syunnichi Saito; Atsushi Kikuta; Kazuei Ogawa; Mikio Ohtsuka; Masafumi Abe; Kenneth E Nollet; Hitoshi Ohto
Journal:  Int J Hematol       Date:  2011-12-14       Impact factor: 2.490

2.  Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes.

Authors:  Keli L Hippen; Christoph Bucher; Dawn K Schirm; Amanda M Bearl; Ty Brender; Kathy A Mink; Kimberly S Waggie; Regis Peffault de Latour; Anne Janin; Julie M Curtsinger; Stacey R Dillon; Jeffrey S Miller; Gerard Socie; Bruce R Blazar
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

3.  IDO in human gut graft-versus-host disease.

Authors:  Philippe Ratajczak; Anne Janin; Régis Peffault de Larour; Lisa Koch; Brigitte Roche; David Munn; Bruce R Blazar; Gérard Socié
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-09       Impact factor: 5.742

Review 4.  Microbiome-intestine cross talk during acute graft-versus-host disease.

Authors:  Hind Rafei; Robert R Jenq
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

5.  Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects.

Authors:  Grégory Ehx; Gilles Fransolet; Laurence de Leval; Stéphanie D'Hondt; Sophie Lucas; Muriel Hannon; Loïc Delens; Sophie Dubois; Pierre Drion; Yves Beguin; Stéphanie Humblet-Baron; Frédéric Baron
Journal:  Oncoimmunology       Date:  2017-04-12       Impact factor: 8.110

6.  An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.

Authors:  Edouard Forcade; Katelyn Paz; Ryan Flynn; Brad Griesenauer; Tohti Amet; Wei Li; Liangyi Liu; Giorgos Bakoyannis; Di Jiang; Hong Wei Chu; Mercedes Lobera; Jianfei Yang; David S Wilkes; Jing Du; Kate Gartlan; Geoffrey R Hill; Kelli Pa MacDonald; Eduardo L Espada; Patrick Blanco; Jonathan S Serody; John Koreth; Corey S Cutler; Joseph H Antin; Robert J Soiffer; Jerome Ritz; Sophie Paczesny; Bruce R Blazar
Journal:  JCI Insight       Date:  2017-06-15

Review 7.  Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new.

Authors:  James M Coghill; Stefanie Sarantopoulos; Timothy P Moran; William J Murphy; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2011-01-18       Impact factor: 22.113

8.  CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response.

Authors:  Brian C Betts; Elizabeth M Sagatys; Anandharaman Veerapathran; Mark C Lloyd; Francisca Beato; Harshani R Lawrence; Binglin Yue; Jongphil Kim; Said M Sebti; Claudio Anasetti; Joseph Pidala
Journal:  J Leukoc Biol       Date:  2015-02-06       Impact factor: 4.962

9.  Clinical significance of the ratio between FOXP3 positive regulatory T cell and interleukin-17 secreting cell in renal allograft biopsies with acute T-cell-mediated rejection.

Authors:  Byung H Chung; Hye J Oh; Shang G Piao; Hyeon S Hwang; In O Sun; Sun R Choi; Hoon S Park; Bum S Choi; Yeong J Choi; Cheol W Park; Yong-Soo Kim; Mi-La Cho; Chul W Yang
Journal:  Immunology       Date:  2012-07       Impact factor: 7.397

10.  Comparative analysis of FoxP3(+) regulatory T cells in the target tissues and blood in chronic graft versus host disease.

Authors:  M M Imanguli; E W Cowen; J Rose; S Dhamala; W Swaim; S Lafond; B Yagi; R E Gress; S Z Pavletic; F T Hakim
Journal:  Leukemia       Date:  2014-02-28       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.